GTHX G1 Therapeutics Inc

Price (delayed)

$21.73

Market cap

$914.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.46

Enterprise value

$672.32M

Highlights
GTHX's equity is up by 38% since the previous quarter and by 7% year-on-year
The company's EPS rose by 29% YoY and by 6% QoQ
The company's quick ratio rose by 25% QoQ but it fell by 16% YoY
GTHX's debt is up by 35% QoQ

Key stats

What are the main financial stats of GTHX
Market
Shares outstanding
42.07M
Market cap
$914.28M
Enterprise value
$672.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.71
Price to sales (P/S)
15.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.72
Earnings
Revenue
$57.36M
EBIT
-$90.6M
EBITDA
-$90.06M
Free cash flow
-$83.45M
Per share
EPS
-$2.46
Free cash flow per share
-$2.05
Book value per share
$5.85
Revenue per share
$1.41
TBVPS
$7.58
Balance sheet
Total assets
$308.56M
Total liabilities
$63.12M
Debt
$37.51M
Equity
$245.44M
Working capital
$271.41M
Liquidity
Debt to equity
0.15
Current ratio
11.6
Quick ratio
11.11
Net debt/EBITDA
2.69
Margins
EBITDA margin
-157%
Gross margin
99.6%
Net margin
-165%
Operating margin
-161%
Efficiency
Return on assets
-36.1%
Return on equity
-46%
Return on invested capital
-345.1%
Return on capital employed
-32%
Return on sales
-157.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GTHX stock price

How has the G1 Therapeutics stock price performed over time
Intraday
-0.55%
1 week
-0.82%
1 month
-0.82%
1 year
3.23%
YTD
20.79%
QTD
-9.68%

Financial performance

How have G1 Therapeutics's revenue and profit performed over time
Revenue
$57.36M
Gross profit
$57.12M
Operating income
-$92.33M
Net income
-$94.67M
Gross margin
99.6%
Net margin
-165%
The company's operating income rose by 32% YoY and by 4.3% QoQ
The company's net income rose by 27% YoY and by 4.6% QoQ
GTHX's revenue is up by 27% QoQ
The gross profit has increased by 26% since the previous quarter

Growth

What is G1 Therapeutics's growth rate over time

Valuation

What is G1 Therapeutics stock price valuation
P/E
N/A
P/B
3.71
P/S
15.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.72
The company's EPS rose by 29% YoY and by 6% QoQ
GTHX's equity is up by 38% since the previous quarter and by 7% year-on-year
The P/B is 10% below the 5-year quarterly average of 4.1
GTHX's revenue is up by 27% QoQ

Efficiency

How efficient is G1 Therapeutics business performance
The ROIC has soared by 98% year-on-year and by 39% since the previous quarter
The company's return on sales rose by 26% QoQ
The ROA has grown by 17% YoY and by 9% from the previous quarter
GTHX's ROE is up by 6% from the previous quarter and by 3.8% YoY

Dividends

What is GTHX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTHX.

Financial health

How did G1 Therapeutics financials performed over time
GTHX's total liabilities has surged by 133% year-on-year and by 23% since the previous quarter
The company's total assets rose by 35% QoQ and by 20% YoY
GTHX's debt is 85% lower than its equity
GTHX's equity is up by 38% since the previous quarter and by 7% year-on-year
GTHX's debt is up by 35% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.